Tdspharm (464280) Fundamentals 2026 — P/E 5.7x, Revenue Analysis | SniperIQ
Tdspharm (464280) is a KR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₩29.0B, trading at ₩5490.00 on the KOE. This SniperIQ fundamentals page covers Tdspharm's valuation (P/E 5.7x, P/B 0.7x), profitability (net margin 16.6%), revenue (₩27.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tdspharm's market cap?
Tdspharm (464280) has a market capitalization of approximately ₩29.0B, trading at ₩5490.00 on the KOE. Market cap moves with the live share price.
What is Tdspharm's P/E ratio?
Tdspharm's trailing twelve-month P/E ratio is 5.7x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tdspharm?
Tdspharm runs a net profit margin of 16.6%, a gross margin of 27.9%, and an operating margin of 16.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tdspharm generate?
Tdspharm reported revenue of ₩27.6B for fiscal year 2025, with net income of ₩4.3B and earnings per share (EPS) of 808. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tdspharm pay a dividend?
Tdspharm does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Tdspharm financially healthy?
Tdspharm carries a debt-to-equity ratio of 0.32x and a current ratio of 2.09x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tdspharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tdspharm (464280) the key facts are: market cap ₩29.0B, P/E 5.7x, revenue ₩27.6B, 52-week range 5220-11650. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tdspharm's full fundamentals live
Get Tdspharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.